메뉴 건너뛰기




Volumn 24, Issue 4, 2008, Pages 191-197

Is it cost-effective to change brand-name to generic simvastatin in Taiwan?

Author keywords

Brand; Conversion; Cost effective; Generic; Simvastatin

Indexed keywords

AMINOTRANSFERASE; CHOLESTEROL; GENERIC DRUG; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ZOLOTIN;

EID: 60849091923     PISSN: 10116842     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (1)

References (16)
  • 1
    • 0023121401 scopus 로고
    • Cholesterol and mortality. 30 years of follow-up from the Framingham study
    • Anderson KM, Castelli WP, Levy D. Cholesterol and mortality. 30 years of follow-up from the Framingham study. J Am Med Assoc 1987;257(16):2170-80.
    • (1987) J Am Med Assoc , vol.257 , Issue.16 , pp. 2170-2180
    • Anderson, K.M.1    Castelli, W.P.2    Levy, D.3
  • 2
    • 0029060065 scopus 로고
    • Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study
    • Verschuren WM, Jacobs DR, Bloemberg BP, et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study. JAMA 1995;274:131-5.
    • (1995) JAMA , vol.274 , pp. 131-135
    • Verschuren, W.M.1    Jacobs, D.R.2    Bloemberg, B.P.3
  • 3
    • 0022417070 scopus 로고
    • Risk factors for ischaemic heart disease: The prospective phase of the British Regional Heart Study
    • Sharper AG, Pocock SJ, Walker M, et al. Risk factors for ischaemic heart disease: the prospective phase of the British Regional Heart Study. J Epidemiol Community Health 1985;39(3): 197-209.
    • (1985) J Epidemiol Community Health , vol.39 , Issue.3 , pp. 197-209
    • Sharper, A.G.1    Pocock, S.J.2    Walker, M.3
  • 4
    • 0027987849 scopus 로고
    • Randomized trial of cholesterol lowering in 444 patients with coronary heart disease: The Scandinavian Sirrivastatin Survival Study (4S)
    • Randomized trial of cholesterol lowering in 444 patients with coronary heart disease: the Scandinavian Sirrivastatin Survival Study (4S). Lancet 1994;44(8934):1383-9.
    • (1994) Lancet , vol.44 , Issue.8934 , pp. 1383-1389
  • 5
    • 0028883828 scopus 로고
    • Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group
    • Shepherd J, Cobbee SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
    • (1995) N Engl J Med , vol.333 , pp. 1301-1307
    • Shepherd, J.1    Cobbee, S.M.2    Ford, I.3
  • 6
    • 0342981862 scopus 로고    scopus 로고
    • The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators
    • Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-9.
    • (1996) N Engl J Med , vol.335 , pp. 1001-1009
    • Sacks, F.M.1    Pfeffer, M.A.2    Moye, L.A.3
  • 7
    • 0032572086 scopus 로고    scopus 로고
    • Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study
    • Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22.
    • (1998) JAMA , vol.279 , pp. 1615-1622
    • Downs, J.R.1    Clearfield, M.2    Weis, S.3
  • 8
    • 0035897696 scopus 로고    scopus 로고
    • Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
    • Executive Summary of the Third Report of the National Cholesterol Education Program NCEP
    • Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
    • (2001) JAMA , vol.285 , pp. 2486-2497
  • 9
    • 0036954887 scopus 로고    scopus 로고
    • National Cholesterol Education Program. Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Full report. September 2002. Available at: http://www.nhlbi.nih.gov/guidelines/cholesterol/ atp3_rpt.htm. Accessed November 2, 2004. Can J Cardiol 1993;9:405-12.
    • National Cholesterol Education Program. Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Full report. September 2002. Available at: http://www.nhlbi.nih.gov/guidelines/cholesterol/ atp3_rpt.htm. Accessed November 2, 2004. Can J Cardiol 1993;9:405-12.
  • 10
    • 33748353843 scopus 로고    scopus 로고
    • Impacts of cost contaimnent strategies on pharmaceutical expenditures of the National Health Insurance in Taiwan, 1996-2003
    • Lee YC, Yang MC, Huang YT, et al. Impacts of cost contaimnent strategies on pharmaceutical expenditures of the National Health Insurance in Taiwan, 1996-2003. Pharmacoeconomics 2006: 24(9):891-902.
    • (2006) Pharmacoeconomics , vol.24 , Issue.9 , pp. 891-902
    • Lee, Y.C.1    Yang, M.C.2    Huang, Y.T.3
  • 11
    • 0038721595 scopus 로고    scopus 로고
    • The Bioequivalence and Theurapeutic Efficacy of Generic Versus Brand-name Psychoactive Drugs
    • Giuseppe Borgherini. The Bioequivalence and Theurapeutic Efficacy of Generic Versus Brand-name Psychoactive Drugs. Clin Ther 2003;25(6):1578-92.
    • (2003) Clin Ther , vol.25 , Issue.6 , pp. 1578-1592
    • Borgherini, G.1
  • 12
    • 0035073507 scopus 로고    scopus 로고
    • United States Food and Drug Administration requirements for approval of generic drug products
    • Meyer MC. United States Food and Drug Administration requirements for approval of generic drug products. J Clin Psychiatry 2001;62(Suppl 5):4-9.
    • (2001) J Clin Psychiatry , vol.62 , Issue.SUPPL. 5 , pp. 4-9
    • Meyer, M.C.1
  • 13
    • 84855752822 scopus 로고    scopus 로고
    • Office of Generic Drugs, Available at:, 16th August, 2007
    • Office of Generic Drugs. US Food and Drug Administration Web site. Available at: http//www.fda.gov/cder/cder/ogd/. (16th August, 2007)
    • US Food and Drug Administration Web site
  • 14
    • 0038632965 scopus 로고    scopus 로고
    • Generic: Not all drugs are created equal
    • Cantor LB. Generic: Not all drugs are created equal. Rev Ophthalmol 2002;9:72-4.
    • (2002) Rev Ophthalmol , vol.9 , pp. 72-74
    • Cantor, L.B.1
  • 15
    • 0033049802 scopus 로고    scopus 로고
    • Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease
    • Schaefer JR, Schweer H, Ikewaki K, et al. Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease. Atherosclerosis 1999;144:177-84.
    • (1999) Atherosclerosis , vol.144 , pp. 177-184
    • Schaefer, J.R.1    Schweer, H.2    Ikewaki, K.3
  • 16
    • 3042681157 scopus 로고    scopus 로고
    • Are the effects of statins on LDL-cholesterol clinically relevant?
    • Chapman MJ. Are the effects of statins on LDL-cholesterol clinically relevant? Eur Heart J 2004;6(Suppl C):C58-C63.
    • (2004) Eur Heart J , vol.6 , Issue.SUPPL. C
    • Chapman, M.J.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.